Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) – Analysts at Jefferies Group issued their Q3 2017 earnings per share estimates for shares of Verona Pharma PLC American Depositary Share in a report released on Tuesday. Jefferies Group analyst P. Welford anticipates that the company will earn ($0.53) per share for the quarter. Jefferies Group currently has a “Buy” rating and a $26.00 price target on the stock. Jefferies Group also issued estimates for Verona Pharma PLC American Depositary Share’s Q4 2017 earnings at ($0.58) EPS, FY2017 earnings at ($2.64) EPS, FY2018 earnings at ($2.85) EPS, FY2019 earnings at ($3.50) EPS, FY2020 earnings at $4.55 EPS and FY2021 earnings at $2.00 EPS.

VRNA has been the topic of several other research reports. Wedbush began coverage on shares of Verona Pharma PLC American Depositary Share in a research report on Monday, May 22nd. They set an “outperform” rating and a $25.00 target price on the stock. Zacks Investment Research raised shares of Verona Pharma PLC American Depositary Share from a “hold” rating to a “buy” rating and set a $14.00 target price on the stock in a research report on Tuesday, July 25th. Stifel Nicolaus began coverage on shares of Verona Pharma PLC American Depositary Share in a research report on Monday, May 22nd. They set a “buy” rating and a $22.00 target price on the stock. Finally, SunTrust Banks, Inc. began coverage on shares of Verona Pharma PLC American Depositary Share in a research report on Monday, May 22nd. They set a “buy” rating and a $26.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $22.60.

TRADEMARK VIOLATION WARNING: This piece of content was first published by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/08/10/equities-analysts-issue-forecasts-for-verona-pharma-plc-american-depositary-shares-q3-2017-earnings-vrna.html.

Shares of Verona Pharma PLC American Depositary Share (NASDAQ VRNA) opened at 12.11 on Thursday. Verona Pharma PLC American Depositary Share has a 1-year low of $11.03 and a 1-year high of $17.50. The company’s market cap is $77.75 million. The firm has a 50-day moving average price of $14.16 and a 200 day moving average price of $13.85.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) last released its quarterly earnings data on Tuesday, August 8th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by $0.09.

An institutional investor recently bought a new position in Verona Pharma PLC American Depositary Share stock. Vivo Capital LLC bought a new stake in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) during the second quarter, according to its most recent filing with the SEC. The institutional investor bought 704,225 shares of the company’s stock, valued at approximately $8,208,000. Verona Pharma PLC American Depositary Share makes up about 2.1% of Vivo Capital LLC’s holdings, making the stock its 11th largest position. Vivo Capital LLC owned about 10.97% of Verona Pharma PLC American Depositary Share as of its most recent filing with the SEC. Institutional investors own 5.09% of the company’s stock.

Verona Pharma PLC American Depositary Share Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, researches, discovers, and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. The company’s lead product is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which is in Phase IIa clinical trial that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, and asthma.

Earnings History and Estimates for Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)

Receive News & Ratings for Verona Pharma PLC American Depositary Share Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma PLC American Depositary Share and related companies with MarketBeat.com's FREE daily email newsletter.